Story thread · 2 reports / 1 sources
MaxCyte reiterates $30M-$32M 2026 revenue outlook as Genentech partnership expands enterprise model
seekingalpha.com · 1h
First report: Harrow reiterates $350M-$365M 2026 revenue outlook as TYRVAYA is expected to add more than $30M in 2027 revenue — seekingalpha.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.